Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 10

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele

Authors Naidoo A, Naidoo K, Ramsuran V, Reddy M, Padayatchi N

Received 19 July 2017

Accepted for publication 28 July 2017

Published 23 August 2017 Volume 2017:10 Pages 233—234


Checked for plagiarism Yes

Editor who approved publication: Dr Martin Bluth

Anushka Naidoo,1 Kogieleum Naidoo,1,2 Veron Ramsuran,3 Millidhashni Reddy,1 Nesri Padayatchi1,2

1Centre for the AIDS Programme of Research in South Africa, 2MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, 3School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
Panagopoulos et al1 reviewed the effects of the UGT1A1*28 polymorphism on Reyataz® (atazanavir)-related hyperbilirubinemia in human immunodeficiency virus (HIV)-infected patients that may result in increased severity and drug discontinuation in some patients. The effects of the UGT1A1 polymorphisms on the pharmacokinetics of other antiretroviral drugs such as Isentress® (raltegravir) and Edurant® (rilpivirine) are also discussed. We respond here on the relevance of the study findings in the South African context. 
View the original paper by Panagopoulos and colleagues. 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]